Genetic and Immunologic Basis of COVID-19 Infection

Genetic Basis of COVID-19 Infection Clinical Trial

Official title:

Genetic Factors Influencing the Response to Infection With SARS-COV-2

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04384250
• Other study ID #: RP:20.05.70
• Status: Active, not recruiting
• Start date: June 1, 2020
• Est. completion date: December 30, 2024

Study information

• Verified date: May 2023
• Source: Mansoura University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

We will study genetic factors causing severe disease due to infection with SARS-COV-2 which may help to find targeted therapy

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 500
• Est. completion date: December 30, 2024
• Est. primary completion date: December 30, 2023
• Gender: All
• Age group: 1 Day to 50 Years

Eligibility

Inclusion Criteria:

• severe COVID-19 infection

Exclusion Criteria:

• Comorbidity ((DM, hypertension, Chronic liver or Kidney diseases, HIV, morbid obesity, Malignancy, Immunosuppressive therapy)

Related Conditions & MeSH terms

• Communicable Diseases
• COVID-19
• Genetic Basis of COVID-19 Infection
• Infections

Intervention

Diagnostic Test:
• Whole Exome Sequencing
Genetic study of patients

Locations

Country	Name	City	State
Egypt	Mansoura University	Mansoura	Dakahlyia

Sponsors (1)

Lead Sponsor	Collaborator
Mansoura University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mutations leading to increase susceptibility to SARS-COV-2 infection	Genetic susceptibility to COVID-19	12 months